Somewhat Positive Media Coverage Somewhat Unlikely to Impact Galapagos (GLPG) Stock Price
Headlines about Galapagos (NASDAQ:GLPG) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Galapagos earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 44.6250107896222 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have effected Accern’s analysis:
- Galapagos NV (GLPG) Provides Update on Cystic Fibrosis Programs (streetinsider.com)
- Galapagos NV (GLPG): FLAMINGO Results Kick Off A Data Rich 2018 – Nomura – StreetInsider.com (streetinsider.com)
- Galapagos NV (GLPG) Provides Update on Cystic Fibrosis Programs – StreetInsider.com (streetinsider.com)
- Update on progress in cystic fibrosis programs (finance.yahoo.com)
- Galapagos (GLPG) Stock Rating Upgraded by BidaskClub (americanbankingnews.com)
Galapagos (GLPG) traded down $0.01 during trading hours on Thursday, reaching $97.33. 44,849 shares of the company’s stock were exchanged, compared to its average volume of 67,267. Galapagos has a 1-year low of $63.69 and a 1-year high of $104.12.
A number of equities analysts recently weighed in on the stock. Zacks Investment Research raised shares of Galapagos from a “sell” rating to a “hold” rating in a research note on Wednesday. BidaskClub raised shares of Galapagos from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 30th. ValuEngine downgraded shares of Galapagos from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Royal Bank of Canada assumed coverage on shares of Galapagos in a research note on Thursday, September 14th. They set a “sector perform” rating and a $98.00 target price for the company. Finally, Morgan Stanley reissued an “overweight” rating and set a $123.00 target price (up previously from $92.00) on shares of Galapagos in a research note on Friday, October 6th. Two analysts have rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the stock. Galapagos currently has a consensus rating of “Hold” and a consensus price target of $111.00.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Galapagos (GLPG) Stock Price” was published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-galapagos-glpg-stock-price/1794765.html.
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.